Table 1. Clinical characteristics of patients with triple-negative breast cancer.
| Factors | N | % |
|---|---|---|
| Total | 62 | |
| Age (years) | ||
| Median (range) | 68 (31–93) | |
| Menopausal status | ||
| Premenopausal | 9 | 14.5 |
| Postmenopausal | 52 | 83.9 |
| Unknown | 1 | 1.6 |
| Body mass index | ||
| Median (range) | 23.2 (16.2–32.2) | |
| Tumor size (mm) | ||
| Median (range) | 20 (2–55) | |
| Pathological stage | ||
| I | 26 | 41.9 |
| IIA | 23 | 37.1 |
| IIB | 5 | 8.1 |
| IIIA | 4 | 6.5 |
| IIIB | 3 | 4.8 |
| IIIC | 1 | 1.6 |
| Lymph node status | ||
| Positive | 14 | 22.6 |
| Negative | 33 | 53.2 |
| Not tested | 15 | 24.2 |
| Lymphatic invasion | ||
| Positive | 53 | 85.5 |
| Negative | 9 | 14.5 |
| Venous invasion | ||
| Positive | 37 | 59.7 |
| Negative | 25 | 40.3 |
| Nottingham histological grade | ||
| 1 | 2 | 3.2 |
| 2 | 28 | 45.2 |
| 3 | 32 | 51.6 |
| Ki-67 labeling index (LI) | ||
| High | 37 | 59.7 |
| Low | 21 | 33.9 |
| Not tested | 4 | 6.5 |
| Stromal tumor-infiltrating lymphocytes | ||
| High | 19 | 30.6 |
| Low/intermediate | 43 | 69.4 |
| Adjuvant chemotherapy | ||
| Performed | 34 | 54.8 |
| Not performed | 25 | 40.3 |
| Undetermined | 3 | 4.8 |